Profile data is unavailable for this security.
About the company
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
- Revenue in USD (TTM)0.00
- Net income in USD-11.12m
- Incorporated2011
- Employees13.00
- LocationProcessa Pharmaceuticals Inc7380 Coca Cola Dr Ste 106HANOVER 21076-1789United StatesUSA
- Phone+1 (443) 776-3133
- Fax+1 (443) 288-4420
- Websitehttps://www.processapharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kineta Inc | 5.44m | -14.10m | 5.53m | 11.00 | -- | 1.75 | -- | 1.02 | -1.43 | -1.43 | 0.5297 | 0.278 | 0.3927 | -- | -- | 494,727.30 | -101.57 | -66.16 | -318.39 | -86.61 | -- | -- | -258.65 | -854.74 | -- | -1,310.25 | 0.2011 | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Biofrontera Inc | 34.07m | -20.13m | 5.55m | 85.00 | -- | 0.3451 | -- | 0.1628 | -15.19 | -15.19 | 24.30 | 3.16 | 0.8646 | 1.93 | 5.42 | 400,858.80 | -51.08 | -- | -101.07 | -- | 48.80 | -- | -59.08 | -- | 0.6727 | -2.71 | 0.4489 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.58m | 4.00 | -- | 0.5615 | -- | 0.6965 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| Emmaus Life Sciences Inc | 28.46m | -4.74m | 5.70m | 55.00 | -- | -- | -- | 0.2003 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
| Azitra Inc | 572.70k | -12.40m | 5.71m | 10.00 | -- | 1.32 | -- | 9.97 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.12m | 5.72m | 13.00 | -- | 0.5155 | -- | -- | -8.72 | -8.72 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -154.40 | -84.35 | -175.45 | -90.03 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| ProtoKinetix, Inc. | 0.00 | -415.48k | 5.76m | 0.00 | -- | 13.19 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0013 | 0.00 | -- | -- | -- | -88.08 | -696.88 | -96.94 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Sonnet Biotherapeutics Holdings Inc | 129.19k | -14.46m | 5.76m | 12.00 | -- | 2.21 | -- | 44.57 | -12.91 | -12.91 | 0.0676 | 0.8381 | 0.0251 | -- | 0.1688 | 10,765.83 | -281.29 | -- | -- | -- | -- | -- | -11,192.09 | -- | -- | -- | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| HST Global Inc | 0.00 | -146.22k | 5.77m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.19m | 5.78m | 2.00 | -- | -- | -- | -- | -0.009 | -0.009 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -84,895.00 | -10,098.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.18 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 5.80m | 5.00 | -- | 2.10 | -- | 12.15 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -7.70m | 5.82m | 2.00 | -- | 0.6691 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.89m | 4.00 | -- | 0.6371 | -- | 654.21 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -15.47m | 5.91m | 2.00 | -- | -- | -- | -- | -0.534 | -0.534 | 0.00 | -0.1322 | 0.00 | -- | -- | 0.00 | -714.74 | -308.05 | -- | -- | -- | -- | -- | -- | -- | -175.42 | -- | -- | -- | -- | -38.08 | -- | -- | -- |
| Titan Pharmaceuticals Inc | 185.00k | -5.57m | 5.93m | 4.00 | -- | 0.7627 | -- | 32.03 | -7.40 | -7.40 | 0.246 | 8.50 | 0.0305 | -- | 4.51 | 46,250.00 | -91.72 | -96.80 | -138.02 | -156.65 | -- | -- | -3,010.27 | -406.26 | 5.55 | -- | 0.07 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Healthy Extracts Inc | 2.49m | -2.47m | 5.93m | -- | -- | 6.19 | -- | 2.38 | -0.8588 | -0.8588 | 0.8611 | 0.3231 | 0.918 | 0.4921 | 36.50 | -- | -91.32 | -53.78 | -174.02 | -146.65 | 65.90 | 45.68 | -99.48 | -87.53 | 0.1636 | -9.72 | 0.5245 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Processa Pharmaceuticals Inc's reporting currency: US Dollar USD
3.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 24.43k | 1.43% |
| Citadel Securities LLCas of 31 Dec 2023 | 15.77k | 0.92% |
| Geode Capital Management LLCas of 31 Dec 2023 | 6.10k | 0.36% |
| UBS Securities LLCas of 31 Dec 2023 | 4.00k | 0.23% |
| Coastal Bridge Advisors LLCas of 31 Dec 2023 | 3.25k | 0.19% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 2.91k | 0.17% |
| RBC Capital Markets LLC (Investment Management)as of 31 Dec 2023 | 2.31k | 0.14% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.14k | 0.13% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 1.41k | 0.08% |
| Two Sigma Investments LPas of 31 Dec 2023 | 934.00 | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
